Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 19Unknown 7Withdrawn 4Recruiting 4Terminated 3

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 18Breast 10Thoracic 4Sarcoma 3Genitourinary 3Gynecologic 2Dermatologic 2CNS 2Tumor-Agnostic 1Plasma cell 1Classical hematology 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Neoadjuvant Therapy × Genitourinary × Clear all
NCT00651326 2023-08-04

DART

Canadian Cancer Trials Group

Phase 3 Terminated
48 enrolled
Genitourinary

Prostatic Neoplasms

NCT00747305 2015-10-22

Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

Medical University of South Carolina

Phase 1 Terminated
17 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00516750 2013-07-10

Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

National Cancer Institute (NCI)

Phase 2 Terminated
100 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡